AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8317687
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg acetylsalicylic acid (ASA) daily
Trial: 8317687
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage groups (40 mg and 500 mg)
Trial: 26063325
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 10 mg per week (FA10)
Trial: 26063325
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 30 mg per week (FA30)
Trial: 21572992
Drug: Adrenaline (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline (0.25 ml of a 1:1,000 solution subcutaneously)
Trial: 21572992
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg intravenously)
Trial: 16790616
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB) 3 mg/kg
Trial: 12627741
Drug: National Institute
RxNorm normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: National Institute on Drug Abuse standard condition
Trial: 10696738
Drug: Concurrent intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent intra-arterial infusion of platinum drugs with radiation therapy (IAPRT)
Trial: 6388315
Drug: Sulfamethoxazole-trimethoprim (oral)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole-trimethoprim (oral) for 14 days
Trial: 6388315
Drug: Pentamidine (intramuscular)
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentamidine (intramuscular) for 14 days
Trial: 30691177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two sensors (pocket and wrist)
Trial: 11300507
Drug: MDMA 100
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 100 mg as a single oral dose
Trial: 6240223
Drug: norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin (400 mg) twice daily for 10 days
Trial: 3070683
Drug: trimethoprim‐sulfamethoxazole (160‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim‐sulfamethoxazole (160‐800 mg) twice daily for 10 days
Trial: 30341453
Drug: SC abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SC abatacept 125 mg/week plus methotrexate (MTX)
Trial: 26630643
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (ER-niacin)
Trial: 23874021
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (20 mg/wk)
Trial: 12876632
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists for 3 months
Trial: 12876632
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists for 6 months
Trial: 12876632
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment durations (3 months and 6 months)
Trial: 3330116
Drug: 40 mg/die
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/die slow release nifedipine
Trial: 31647124
Drug: Treatment response
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment response (continued-improvers)
Trial: 31647124
Drug: Treatment response
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment response (halted-improvers)
Trial: 23931044
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate infusion (0.5 mmol/kg bolus followed by 0.2 mmol/kg/hour infusion)
Trial: 20494931
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (control group)
Trial: 12785458
Drug: Tramadol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (75 mg or 112.5 mg) plus Acetaminophen (650 mg or 975 mg)
Trial: 12785458
Drug: Tramadol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (75 mg or 112.5 mg)
Trial: 12785458
Drug: Acetaminophen (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (650 mg or 975 mg)
Trial: 30303612
Drug: Tramadol/Acetaminophen combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol/Acetaminophen combination
Trial: 10687148
Drug: Cohort 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by peripheral blood stem cell infusion and granulocyte colony-stimulating factor at 10 micrograms/kg
Trial: 10687148
Drug: Cohort 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: CTCb plus rhIL-2 (2 x 10(6) IU/m2/day) for 4 days intravenously via continuous infusion after peripheral blood stem cell infusion
Trial: 10687148
Drug: Cohort 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: CTCb followed by infusion of autologous activated NK cells and rhIL-2 (2 x 10(6) IU/m2/day) for 4 days via continuous intravenous infusion
Trial: 8567973
Drug: Low-dose (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (0.025 U/kg) infusion over 10 min
Trial: 8567973
Drug: Low-dose (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (0.025 U/kg) bolus injection
Trial: 8567973
Drug: High-dose (0.050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (0.050 U/kg) bolus injection
Trial: 2872054
Drug: Propranolol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (8 mg i.v.)
Trial: 2872054
Drug: Pindolol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (0.8 mg i.v.)
Trial: 29538506
Drug: Control (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Standard Medical Treatment)
Trial: 25168488
Drug: Stable background
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable background AD medication
Trial: 25168488
Drug: Control-arm data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control-arm data (placebo and stable background AD medication)
Trial: 19674789
Drug: cediranib (RECENTIN™)
RxNorm normalized name: cediranib
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cediranib (RECENTIN™) at doses of ≤30 mg/day
Trial: 18279553
Drug: Plant stanol
RxNorm normalized name: plant stanol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant stanol esters mixed with vegetable oil spreads (2 g/d)
Trial: 15752828
Drug: Virosomal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal vaccine (Epaxal)
Trial: 15752828
Drug: Aluminum-adsorbed vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum-adsorbed vaccine (Havrix 1440)
Trial: 12883493
Drug: peginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2b 1.5 mcg per kg and ribavirin for 48 weeks
Trial: 10583450
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 100 IU daily, increased to 1600 IU daily
Trial: 8934240
Drug: Routine monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine monthly changes of percutaneous feeding tubes
Trial: 1875728
Drug: Low therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low therapeutic dosage of methionyl‐human growth hormone (met‐hGH)
Trial: 1875728
Drug: High therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High therapeutic dosage of methionyl‐human growth hormone (met‐hGH)
Trial: 1875728
Drug: Methionyl‐human growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionyl‐human growth hormone (met‐hGH) supplementation
Trial: 26923616
Drug: Immediate auditory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate auditory feedback therapy
Trial: 26923616
Drug: Jittered auditory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jittered auditory feedback therapy
Trial: 25275520
Drug: Pomegranate fruit
RxNorm normalized name: Pomegranate Fruit
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate fruit extract and galangal rhizome (Punalpin) tablets taken daily for three months
Trial: 25275520
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken daily for three months
Trial: 16189518
Drug: S-1 2-week
RxNorm normalized name: (S)-1-phenyl-2-aminopropane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 2-week administration followed by 1-week rest for 6 months (arm A)
Trial: 16189518
Drug: S-1 4-week
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: S-1 4-week administration followed by 2-week rest for 6 months (arm B)
Trial: 2100969
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy combination
Trial: 2100969
Drug: Portal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portal infusion of cytotoxic drugs
Trial: 28094477
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Trial: 28094477
Drug: Dexmedetomidine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion)
Trial: 28094477
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine (0.5 µg/kg loading, 0.4 µg/kg/h infusion)
Trial: 19289630
Drug: Methotrexate 40
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40 mg/m2 intravenously weekly
Trial: 15235059
Drug: L‐DOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐DOPA
Trial: 20634797
Drug: Quinapril (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (40 mg/day)
Trial: 7917794
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of atenolol (50 mg) and nifedipine (20 mg)
Trial: 3057810
Drug: Genotropin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin (recombinant somatropin) with 6-7 injections/week
Trial: 3057810
Drug: Genotropin (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotropin (recombinant somatropin) with 2-3 injections/week
Trial: 22253268
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in Ringer lactate solution
Trial: 22253268
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer lactate solution (control)
Trial: 21897343
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with local anesthetic, lidocaine 0.5%, 10 mL
Trial: 21897343
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural injections with 0.5% lidocaine, 9 mL, mixed with 1 mL of steroid
Trial: 18420558
Drug: Randomized responding
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized responding technique (RRT) treatment group
Trial: 9316691
Drug: Nimodipine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (120 mg/day)
Trial: 20022777
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with agalsidase alfa or agalsidase beta in Cohort 1B
Trial: 20022777
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) prior to October 2006 in Cohort 1A
Trial: 18710324
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPV) followed by protein‐conjugate pneumococcal vaccine (PCV)
Trial: 18710324
Drug: Protein‐conjugate pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein‐conjugate pneumococcal vaccine (PCV) followed by pneumococcal polysaccharide vaccine (PPV)
Trial: 18710324
Drug: Protein‐conjugate pneumococcal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein‐conjugate pneumococcal vaccine (PCV)
Trial: 18710324
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PPV) as a booster after PCV
Trial: 15695301
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (thalassotherapy, supervised exercise, and group education)
Trial: 15695301
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (treatment as usual)
Trial: 12112158
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication alone (Control)
Trial: 2210464
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg daily for 12 weeks
Trial: 2210464
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg daily for 12 weeks plus cefixime 100 mg daily for the last two weeks
Trial: 31296884
Drug: Nitisinone 1
RxNorm normalized name: nitisinone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitisinone 1 mg daily
Trial: 31296884
Drug: Nitisinone 2
RxNorm normalized name: nitisinone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitisinone 2 mg daily
Trial: 31296884
Drug: Nitisinone 4
RxNorm normalized name: nitisinone 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitisinone 4 mg daily
Trial: 31296884
Drug: Nitisinone 8
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nitisinone 8 mg daily
Trial: 24112746
Drug: Titrated oral
RxNorm normalized name: magnesium citrate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titrated oral misoprostol solution (initial dose 20μg/hour, increased by 20μg/hour every 6 hours up to 80μg/hour for a maximum of 48 doses)
Trial: 24112746
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol tablets (25μg every 6 hours for a maximum of 8 doses)
Trial: 21900191
Drug: Taliglucerase alfa
RxNorm normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taliglucerase alfa (30 U/kg body weight/infusion)
Trial: 21900191
Drug: Taliglucerase alfa
RxNorm normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taliglucerase alfa (60 U/kg body weight/infusion)
Trial: 19638025
Drug: Dual-task conditions
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-task conditions (oral counting task)
Trial: 17717929
Drug: Modified Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Xiaoyao Pill combining amitriptyline (MXP-At)
Trial: 17717929
Drug: Fluoxetine (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (control group)
Trial: 11587992
Drug: Anticoagulant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant therapy (3 months)
Trial: 9519224
Drug: Budesonide 4
RxNorm normalized name: budesonide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 4 mg nebulized suspension
Trial: 9519224
Drug: Budesonide 1
RxNorm normalized name: BUDESONIDE 1MG/2ML SUSP,INH,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 1 mg nebulized suspension
Trial: 9519224
Drug: Budesonide 0.8
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.8 mg pMDI with spacer
Trial: 2511532
Drug: Depot gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot gonadotropin-releasing hormone analogue (leuprolide) given monthly for 24 weeks
Trial: 887103
Drug: Oral choline
RxNorm normalized name: choline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral choline administration for two weeks
Trial: 30093401
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (2.5-10 mg/m2) administered in 1-4 cycles as a single agent (47%), combined with cytarabine (47%), or others (6%)
Trial: 19737502
Drug: Paper-and-pencil Daily
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paper-and-pencil Daily Social Diary (DSD)
Trial: 17714104
Drug: 15 milliTESLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 milliTESLA (mT) treatment using a prototype electromagnetic field device
Trial: 15113951
Drug: Medicinal iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicinal iron supplements
Trial: 9439541
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) infusion (25 ng/kg/min)
Trial: 7886779
Drug: Aminosidine, 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminosidine, 14 mg/kg/d (max. 1 g daily) for 20 days
Trial: 7886779
Drug: Sodium stibogluconate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium stibogluconate, 20 mg/kg/d for 20 days
Trial: 26163093
Drug: Chemotherapy (CHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHT) followed by short-course palliative RT: 2-3 platinum-based CHT cycles followed by 10Gy in a single fraction or 16Gy in 2 fractions (arm B)
Trial: 15126606
Drug: Pre-diagnostic plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-diagnostic plasma selenium levels (5th versus 1st quintile) among case subjects with elevated baseline PSA levels (PSA >4 ng/mL)
Trial: 7572650
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg 4 times daily
Trial: 1690482
Drug: Prazosin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial)
Trial: 376211
Drug: Trazodone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50 mg) 3 times a day
Trial: 376211
Drug: Imipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (25 mg) 3 times a day
Trial: 7910886
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg followed by 250 mg daily for 7 days
Trial: 26674497
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (oxycodone and pregabalin) plus magnesium oxide
Trial: 26674497
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (oxycodone and pregabalin) plus placebo
Trial: 22930240
Drug: PTH(1-84) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) treatment over 24 months
Trial: 22930240
Drug: PTH(1-84) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) treatment with ≥80% adherence
Trial: 22930240
Drug: PTH(1-84) treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) treatment
Trial: 22930240
Drug: Post-discontinuation of
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation of PTH(1-84) treatment